Sunzen disposes of loss-making animal health subsidiaries for RM17.3mil


PETALING JAYA: Sunzen Group Bhd is disposing of its loss-making animal health subsidiaries, Sunzen Corp Sdn Bhd (SCSB) and Sunzen Lifesciences Sdn Bhd (SLSB) to Pure Nutritional Products Sdn Bhd for RM17.3mil.

In a statement, Sunzen said the transaction is part of the group’s ongoing transformation to streamline its business focus, enhance profitability, and strengthen its balance sheet.

“SCSB and SLSB, which have been engaged in biotechnology research and development and animal health products, reported combined losses of RM4.1mil for the financial period ended June 30, 2024.

“Following the disposal, these loss-making subsidiaries will cease to be part of Sunzen, allowing the group to focus on its core businesses, including health products, medical devices and services, and loan financing.

Sunzen group managing director Teo Yek Ming said the disposal is a decisive step in optimising its business portfolio.

“By exiting the animal health sector, which recorded losses in the last financial period, we are strengthening our balance sheet and enhancing profitability.

“The one-off disposal gains of approximately RM2.25mil will immediately bolster our financial position and allow us to consolidate and enhance our business ecosystem, particularly in our high-growth segments.”

Follow us on our official WhatsApp channel for breaking news alerts and key updates!
Sunzen , Pure Nutritional

Next In Business News

Perak Corp inks collaboration to secure concession for Perak smart water meter initiative
Ringgit retreats after an eight-day rally
U Mobile inks RM4.3bil financing to support next gen 5G network deployment
Bursa Malaysia ends lower, tracking regional, Wall St downturn
Ark Resources inks JV to develop RM275mil GDV residential project in Penang
Tan Chong Motor subsidiary inks LoI with Perodua
Tropicana Corp issues RM300mil sukuk wakalah
PETRONAS declares commerciality of Sloanea field in Suriname Block 52
Bank Negara cautiously optimistic on FDI inflow into Malaysian in 2026
Main Market-bound LAC Med to raise RM55.6mil in IPO

Others Also Read